Jay Olson
Stock Analyst at Oppenheimer
(4.26)
# 403
Out of 5,147 analysts
250
Total ratings
46.04%
Success rate
18.97%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Initiates: Outperform | $60 | $22.27 | +169.42% | 1 | Feb 25, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $540 | $496.83 | +8.69% | 1 | Feb 13, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $24.56 | -6.35% | 16 | Feb 6, 2026 | |
| BIIB Biogen | Maintains: Outperform | $205 → $225 | $191.82 | +17.30% | 26 | Jan 30, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $75 → $150 | $102.02 | +47.03% | 10 | Jan 27, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $1.67 | +498.80% | 1 | Jan 22, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $250 → $750 | $336.75 | +122.72% | 3 | Dec 15, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $28 → $58 | $42.12 | +37.70% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $600 → $650 | $432.00 | +50.46% | 12 | Nov 20, 2025 | |
| IBIO iBio, Inc. | Initiates: Outperform | $5 | $2.82 | +77.30% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $90 | $81.15 | +10.91% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $30 | $4.99 | +501.20% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $44 | $5.73 | +667.89% | 4 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $3.63 | +285.67% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.67 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $3.99 | +1,529.07% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $1.38 | +4,610.14% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.81 | +618.23% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $68.98 | +30.47% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $21.18 | +98.30% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $44.06 | -25.10% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $13.78 | +190.28% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $4.56 | +338.60% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $5.71 | +425.39% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $101.27 | -19.03% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $29.58 | -66.19% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $33.84 | +307.80% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.61 | +206.51% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $388.16 | -2.10% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $132.25 | +65.60% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.20 | +445.45% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $4.10 | +339.02% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $20.47 | +388.52% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $60.14 | +57.96% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.74 | +3,256.16% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.09 | +725.69% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.38 | +36,131.88% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $14.30 | +46.85% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.56 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.30 | +385.55% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.26 | - | 3 | Jul 11, 2017 |
BioAge Labs
Feb 25, 2026
Initiates: Outperform
Price Target: $60
Current: $22.27
Upside: +169.42%
Vertex Pharmaceuticals
Feb 13, 2026
Upgrades: Outperform
Price Target: $540
Current: $496.83
Upside: +8.69%
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $24.56
Upside: -6.35%
Biogen
Jan 30, 2026
Maintains: Outperform
Price Target: $205 → $225
Current: $191.82
Upside: +17.30%
Revolution Medicines
Jan 27, 2026
Maintains: Outperform
Price Target: $75 → $150
Current: $102.02
Upside: +47.03%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $1.67
Upside: +498.80%
Praxis Precision Medicines
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $336.75
Upside: +122.72%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $28 → $58
Current: $42.12
Upside: +37.70%
Madrigal Pharmaceuticals
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $432.00
Upside: +50.46%
iBio, Inc.
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $2.82
Upside: +77.30%
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $81.15
Upside: +10.91%
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $4.99
Upside: +501.20%
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $5.73
Upside: +667.89%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.63
Upside: +285.67%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $8.67
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $3.99
Upside: +1,529.07%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $1.38
Upside: +4,610.14%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.81
Upside: +618.23%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $68.98
Upside: +30.47%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $21.18
Upside: +98.30%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $44.06
Upside: -25.10%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $13.78
Upside: +190.28%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $4.56
Upside: +338.60%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $5.71
Upside: +425.39%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $101.27
Upside: -19.03%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $29.58
Upside: -66.19%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $33.84
Upside: +307.80%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $2.61
Upside: +206.51%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $388.16
Upside: -2.10%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $132.25
Upside: +65.60%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.20
Upside: +445.45%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $4.10
Upside: +339.02%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $20.47
Upside: +388.52%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $60.14
Upside: +57.96%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.74
Upside: +3,256.16%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.09
Upside: +725.69%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.38
Upside: +36,131.88%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $14.30
Upside: +46.85%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.56
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.30
Upside: +385.55%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.26
Upside: -